The Cardinal Health Monoject insulin syringes. [Image from the FDA] The FDA deemed a recall of Cardinal Health (NYSE:CAH) insulin syringe luer lock packs as type I, the most serious kind of recall.
Get up to 30% off detailed market research reports-for a limited time only! The insulin patch pumps market size is expected to see rapid growth in the next few years. It will grow to $2.16 billion ...
Insulin pump therapy, also known as continuous subcutaneous insulin infusion (CSII), is an important and evolving form of insulin delivery, which is mainly used for people with type 1 diabetes.
Insulet has persuaded a jury that rival South Korean company EOFlow stole trade secrets relating to its wearable insulin pump technology, awarding it a whopping $452 million in damages.
In July, Embecta, a manufacturer of disposable insulin pen needles and syringes, said it is considering ... from the discontinuation of its patch pump program. In total, Embecta expects between ...
The published evidence identified also showed that insulin administration via NovoPen ® devices was for most patients easier, more convenient and quicker than with conventional syringes and that ...
Embecta said Tuesday that it will cancel its insulin patch pump program just months after receiving clearance from the Food and Drug Administration for its first product. The Parsippany, New ...
A federal jury has sided with Insulet, which claimed that the South Korea-based diabetes tech company EOFlow had stolen trade secrets related to its wearable insulin pump, in a case that ...